Zika virus treatment of CD24-positive tumors and diseases associated with abnormal T cell activation and treating or preventing Zika virus infections
AssigneeThe Nemours Foundation
InventorsKenneth Andrew Alexander, Joseph Mazar, Tamarah Jeanette Westmoreland
Life of this patent
Estimating the term…
Abstract
CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and/or preventing Zika virus infection in a subject.
Claims16
A pharmaceutical composition comprising:
- (a) a naked viral RNA of an oncolytic Zika virus in a liposome or a micelle and a pharmaceutically acceptable carrier, or
- (b) a pharmaceutically acceptable carrier and a unit dosage form of an oncolytic Zika virus,
- wherein the naked RNA of the oncolytic Zika virus or the oncolytic Zika virus is in an amount sufficient to reduce the size of a CD24 positive tumor upon administration to a subject in need of treatment for a CD24 positive tumor, and wherein the oncolytic Zika virus is selected from the group consisting of:
- PRVABC59, MR766 and IBH30656.
A combination therapy comprising a pharmaceutical composition of
- (a) a naked viral RNA of an oncolytic Zika virus in a liposome or a micelle and a pharmaceutically acceptable carrier, or
- (b) a pharmaceutically acceptable carrier and a unit dosage form of an oncolytic Zika virus
- and an immunosuppressive therapy that enhances cell lysis induced by administration of the naked viral RNA of an oncolytic Zika virus or the oncolytic Zika virus, and wherein the oncolytic Zika virus is selected from the group consisting of:
- PRVABC59, MR766 and IBH30656.
Dependencies are inferred from the claim text.